Navigation Links
Study Finds Disparities in Breast Cancer Treatment Even Among Fully-Insured African-American and Caucasian Women
Date:6/1/2008

WellPoint's Health Outcomes Research Subsidiary HealthCore Presents Data on Contributing Factors and Steps that Could Be Taken to Improve Treatment of

Women with Breast Cancer and Reduce Disparities

INDIANAPOLIS, June 1 /PRNewswire-FirstCall/ -- HealthCore today presented a study [Abstract No: 6593] comparing treatment patterns and adherence to established treatment guidelines for newly diagnosed breast cancer patients at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. While previous research has shown a relationship between the African-American race and increased breast cancer mortality in the general population, HealthCore sought to understand why similarly increased rates exist even among African-American women with health insurance.

The study, funded by Amgen, analyzed administrative claims data and patient medical charts for more than 3,000 Blue Cross and Blue Shield of Georgia (BCBSGA) members who were diagnosed with breast cancer between January 2000 and August 2005. HealthCore chose to evaluate disparities in care among the insured population to help health plans and physicians identify opportunities and strategies to improve outcomes for women with breast cancer.

"Our data indicates that while significant disparities in care still exist between African-American and Caucasian women, steps can be taken to reduce these differences among the fully insured population," said Louise Short, M.D, MSc, lead investigator for the study and Director of HealthCore's Integrated Research Network.

HealthCore researchers found the factors predicting worse outcomes for African-American vs. Caucasian women with newly diagnosed breast cancer in a fully insured population were consistent with those factors identified by the current medical literature for the general population. The contributing factors HealthCore identified included: diagnosis at a younger age (49.4 vs. 52.4 years; p<0.01) and later stage (p=0.008): a lower prevalence of hormone positive disease (56 percent vs. 75 percent; p<0.01): lower rates of hormone therapy for certain types of patients; and higher prevalence of hypertension (46.5 percent vs. 21.6 percent; p<0.01). In a commercially-insured population, these findings highlight the importance of developing culturally sensitive and targeted interventions to increase earlier detection of breast cancer in African-Americans, increase the percentage of patients that receive hormonal therapy when it is indicated, and include management of co-morbid conditions.

"BCBSGA and other WellPoint companies are developing approaches to assist physicians in treatment documentation while working to raise awareness of earlier detection of breast cancer and treatment options for the disease among African-American women in Georgia," said Sandra White, M.D., medical director for BCBSGA.

According to the Centers for Disease Control and Prevention (CDC), aside from non-melanoma skin cancer, breast cancer is the most common form of cancer in women. Breast cancer is the number one cause of cancer death in Hispanic women and the second most common cause of cancer death in Caucasian, African-American, Asian/Pacific Islander, and American Indian/Alaska Native women.

"In an effort to improve overall quality of cancer care, it's critical to examine disparities in treatment facing different populations," said Otis Brawley, M.D., Chief Medical Officer for the American Cancer Society (ACS) and a co-author on the study. "This study is among the first to examine the care received by a fully-insured population, and our data shows that while health insurance is an important predictor of the quality of care an individual receives, it's not the only factor. African-American women with insurance often do not receive the same level of care as their Caucasian counterparts, and we must work to improve care and outcomes among this population."

HealthCore, a subsidiary of WellPoint, is a health outcomes and clinical research organization that has served the needs of health plans, government agencies, physician practices and pharmaceutical manufacturers since 1996. HealthCore focuses on providing evidence of the real-world safety and effectiveness of therapeutics; offering insight to best utilize this evidence; and communicating these findings to health care decision-makers. The company's work is increasingly used to support evidence-based medicine, process improvement and patient-reported outcomes.

About WellPoint, Inc.

WellPoint, Inc. (NYSE: WLP) is the largest publicly traded commercial health benefits company in terms of membership in the United States. WellPoint, Inc. is an independent licensee of the Blue Cross Blue Shield Association and serves its members as the Blue Cross licensee for California; the Blue Cross and Blue Shield licensee for Colorado, Connecticut, Georgia, Indiana, Kentucky, Maine, Missouri (excluding 30 counties in the Kansas City area), Nevada, New Hampshire, New York (as Blue Cross Blue Shield in 10 New York City metropolitan counties and as Blue Cross, Blue Shield or Blue Cross Blue Shield in selected upstate counties only), Ohio, Virginia (excluding the Northern Virginia suburbs of Washington, D.C.), Wisconsin; and through UniCare. Additional information about WellPoint is available at http://www.wellpoint.com .


'/>"/>
SOURCE WellPoint, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , Jan 17, 2017 Research and ... Market 2016-2020" report to their offering. ... The global laparotomy sponges market to ... Global Laparotomy Sponges Market 2016-2020, has been prepared ... The report covers the market landscape and its growth prospects over ...
(Date:1/17/2017)...  ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ... Quinn Ph.D as Vice President Corticotropin Regulatory Affairs, ... Karen Quinn is a professional with over ... Affairs, specifically with a focus on drug products ... most recently with Takeda Pharmaceuticals International as Senior ...
(Date:1/17/2017)... , Jan. 17, 2017  Bayer today announced the appointment ... Pharmaceuticals business in the Americas, comprising the United ... Latin America . In this role, Dr. ... the Board of Management of Bayer AG and President of ... highly respected leader in the pharmaceutical industry and I,m delighted ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 2017 , ... Neil H. Greco Insurance Agency, a northern New Jersey firm ... is launching a charity drive to raise awareness of heart disease and promote habits ... America, and is responsible for 1 in every 4 deaths at the national level ...
(Date:1/17/2017)... ... January 17, 2017 , ... Physicians Education ... Lee as keynote speaker for the 34th Annual Miami Breast Cancer Conference®, on ... announcement, PER® president, Phil Talamo, said, “We are delighted to have Sandra Lee ...
(Date:1/17/2017)... ... January 17, 2017 , ... Twelve ... State University’s Athletic Training Education program forged a relationship built upon the foundation ... Program, which is consists of both student members and certified members of the ...
(Date:1/16/2017)... Village, IL (PRWEB) , ... January 16, 2017 ... ... personal audio products, will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at ... Convention Center in Las Vegas, Booth #2809. The SHOT Show is the shooting, ...
(Date:1/16/2017)... ... January 16, 2017 , ... Permobil has just ... brand of custom seating systems has a well-earned reputation for premium quality, with ... for innovation and growth in the custom seating business, which enjoys strong demand, ...
Breaking Medicine News(10 mins):